CoChat

The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): Design and baseline characteristics

Jones, Roy W., Kivipelto, Miia, Feldman, Howard, Sparks, Larry, Doody, Rachelle, Waters, David D., Hey-Hadavi, Judith, Breazna, Andrei, Schindler, Rachel J., Ramos, Harry, LEADe investigators · 2008 · Alzheimer's & Dementia
Cited by 71

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Background: Growing evidence suggests that elevated cholesterol levels in mid‐life are associated with increased risk of developing Alzheimer's disease (AD), and that statins might have a protective effect against AD and dementia. The Lipitor's Effect in Alzheimer's Dementia (LEADe) study tests the hypothesis that a statin (atorvastatin 80 mg daily) will provide a benefit on the course of mild to moderate AD in patients receiving background therapy of a cholinesterase inhibitor (donepezil 10 mg daily). Methods: This is an international, multicenter, double‐blind, randomized, parallel‐group study with a double‐blind randomized withdrawal phase of patients with mild to moderate AD (Mini‐Mental State Examination [MMSE] score, 13 to 25). Inclusion criteria included age 50 to 90 years, receiving donepezil 10 mg for at least 3 months before randomization, and low‐density lipoprotein cholesterol levels (LDL‐C) 2.5 to 3.5 mmol/L (95 to 195 mg/dL). Co‐primary end points are changes in AD Assessment Scale‐cognitive subscale (ADAS‐cog) and AD Cooperative Study‐Clinical Global Impression of Change (ADCS‐CGIC) scale scores. A confirmatory end point is rate of change in whole brain and hippocampal volumes in patients who enrolled in the magnetic resonance imaging substudy. Results: Enrollment of 641 subjects is complete. The baseline mean data are age 74 ± 8 years, 53% women, MMSE 22 ± 3, ADAS‐cog 23 ± 10, AD Functional Assessment and Change Scale (ADFACS) 13 ± 9, Neuropsychiatric Inventory (NPI) 10 ± 11, and Clinical Dementia Rating‐Sum of Boxes (CDR‐SB) 6 ± 3. Mean prior donepezil treatment was 409 ± 407 days. Mean baseline lipid levels are total cholesterol 5.8 ± 0.8 mmol/L (224 ± 33 mg/dL), LDL‐C 3.7 ± 0.7 mmol/L (143 ± 26 mg/dL), triglycerides 1.5 ± 0.7 mmol/L (132 ± 64 mg/dL), and high‐density lipoprotein cholesterol 1.6 ± 0.5 mmol/L (64 ± 18 mg/dL). Conclusions: LEADe will report in 2008 and is expected to provide a more definitive evaluation of the potential for statins in the treatment of people with AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2008.02.001

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 45

  1. 10.2105/AJPH.88.9.1337 · DOI · Paper page
  2. 10.1177/089198879600900201 · DOI
  3. 10.1001/archneur.59.3.378 · DOI · Paper page
  4. 10.1212/WNL.57.8.1447 · DOI · Paper page
  5. 10.1212/01.WNL.0000070182.02537.84 · DOI · Paper page
  6. 10.1016/0197-4580(90)90024-T · DOI · Paper page
  7. 10.1016/S0197-4580(00)83093-6 · doi:10.1016/s0197-4580(00)83093-6
  8. 10.1111/j.1600-0404.2006.00687.x · DOI · Paper page
  9. 10.1126/science.8346443 · DOI · Paper page
  10. 10.1016/S0140-6736(00)03155-X · DOI · Paper page
  11. 10.1001/archneur.59.2.223 · DOI · Paper page
  12. 10.1001/archneur.57.10.1439 · DOI · Paper page
  13. 10.1186/1741-7015-5-20 · DOI · Paper page
  14. 10.1212/01.WNL.0000142963.90204.58 · DOI · Paper page
  15. 10.1001/archneur.62.7.1047 · DOI · Paper page
  16. ZArvanitakis JASchneider RSWilson JLBienias JFKelly DAEvans et al.Statins incident Alzheimer disease change in cognitive function and neuropathology. Neurology (in press).
  17. 10.1016/S0140-6736(02)09327-3 · DOI · Paper page
  18. 10.1016/S0140-6736(05)67394-1 · DOI · Paper page
  19. 10.1073/pnas.081620098 · DOI · Paper page
  20. 10.1073/pnas.95.11.6460 · DOI · Paper page
  21. 10.1002/ana.10292 · DOI · Paper page
  22. 10.1159/000084550 · DOI · Paper page
  23. 10.1159/000069989 · DOI · Paper page
  24. 10.1001/archneur.62.5.753 · DOI · Paper page
  25. 10.1111/j.1600-0404.2006.00688.x · DOI · Paper page
  26. 10.1097/00001756-200109170-00036 · DOI
  27. 10.1111/j.1600-0404.2006.00690.x · DOI · Paper page
  28. 10.1111/j.1600-0404.2006.00684.x · DOI · Paper page
  29. 10.1161/01.CIR.0000091404.09558.AF · DOI · Paper page
  30. 10.1161/01.CIR.103.1.113 · DOI · Paper page
  31. 10.1161/hc2401.092816 · DOI · Paper page
  32. American Psychiatric Association, 1987, Diagnostic and statistical manual of mental disorders
  33. 10.1212/WNL.34.7.939 · DOI · Paper page
  34. 10.1016/0022-3956(75)90026-6 · DOI · Paper page
  35. 10.1016/j.ahj.2004.07.025 · DOI
  36. 10.1016/j.amjopharm.2006.06.001 · DOI
  37. 10.1212/WNL.57.3.481 · DOI · Paper page
  38. 10.1212/WNL.57.3.489 · DOI · Paper page
  39. 10.1176/ajp.141.11.1356 · DOI · Paper page
  40. 10.1097/00002093-199700112-00004 · DOI · Paper page
  41. 10.1212/WNL.50.1.136 · DOI · Paper page
  42. 10.1159/000091790 · DOI · Paper page
  43. 10.1001/archinte.158.9.1021 · DOI · Paper page
  44. 10.1212/01.wnl.0000256368.57375.b7 · DOI · Paper page
  45. 10.1001/archneur.64.1.103 · DOI · Paper page

Cited by

See all 71

Metadata

Authors
Jones, R. W., Kivipelto, M., Feldman, H., Sparks, L., Doody, R., Waters, D. D., Hey-Hadavi, J., Breazna, A., Schindler, R. J., Ramos, H., & LEADe investigators
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2008-03
Volume
4
Issue
2
Pages
145-153
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
OpenAlex
W2010754109
Cited by
71
References
7
FWCI
7.73
Type
journal article
Language
en
Open access
closed
Funders
  • Pfizer
  • Eisai
  • Novartis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): Design and baseline characteristics. https://app.cochat.ai/papers/10.1016/j.jalz.2008.02.001
The paper
Jones, R. W., Kivipelto, M., Feldman, H., Sparks, L., Doody, R., Waters, D. D., Hey-Hadavi, J., Breazna, A., Schindler, R. J., Ramos, H., & LEADe investigators. (2008). The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): Design and baseline characteristics. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2008.02.001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.